F10 and venous thromboembolism: In a retrospective review of 30,499 unilateral TKA patients receiving either 325 mg aspirin daily, low-molecular-weight heparin (enoxaparin 40–60 mg daily), synthetic pentasaccharide factor Xa inhibitors (fondaparinux 2.5 mg daily), or vitamin K antagonist (warfarin, all doses), Cafri et al. reported no difference with aspirin when compared to the other agents in the prevention of pulmonary embolism, deep vein thrombosis or venous thromboembolism.